病原体感染及其免疫逃逸机制研究进展

病原体进入宿主后,可通过多种致病机制损伤机体。与此同时,病原体为维持其在宿主体内的生存繁殖,可通过各种方式逃避宿主免疫系统的攻击。简要介绍了病毒、细菌及寄生虫主要的感染及免疫逃逸机制。     

EB病毒免疫逃逸的分子机制

EB病毒(Epstein-Barr vius,EBV)是一种最广泛的对人类感染的γ疱疹病毒,与人类多种疾病尤其是恶性肿瘤有关。其致病的一个重要条件是能够在人体B细胞中长期潜伏,并且在人体免疫力低下时被激活并增殖,这表明EB病毒存在逃逸宿主细胞免疫的机制。从潜伏期EB病毒基因表达的下调、干扰抗原加工和提呈、调节细胞毒性T细胞(Cytotoxic lymphocyte,CTL)免疫应答、干扰细胞因子的作用、干扰CTL的活动及抑制宿主细胞凋亡、抑制辅助性T细胞1(Helper T cell 1,Th1)免疫应答等方面,对EB病毒免疫逃逸的分子机制作一简要综述。     

衣原体调控宿主细胞凋亡的机制研究进展

衣原体是一类专性细胞内寄生的原核微生物,常引起性传播疾病、失明和肺炎等疾病。衣原体可能已经进化出调控宿主细胞的若干机制,通过改变宿主细胞蛋白位置,干扰宿主细胞凋亡信号通路等来抑制细胞凋亡,维持其自身的存活,核转录因子NF-κB也涉及到衣原体感染细胞凋亡抑制;衣原体可以经半胱氨酸蛋白酶依赖途径等机制诱导细胞凋亡,进而感染邻近细胞。     

肾透明细胞癌中免疫检查点相关的免疫逃逸机制的研究进展

摘要：近年来,免疫治疗在晚期肾透明细胞癌的治疗中异军突起,使人们对于肾癌治疗有了全新的认识。肿瘤免疫治疗药物是通过抑制免疫检查点从而抑制肿瘤细胞免疫逃逸,使免疫细胞可以杀伤肿瘤细胞来发挥治疗作用。因此,了解肾透明细胞癌中免疫检查点相关免疫逃逸机制对于制定有效的治疗策略以及开发新的免疫治疗药物至关重要。本文对目前肾透明细胞癌中主要的免疫检查点（PD-1/PD-L1、CTLA-4、B7-H4、LAG-3、TIM-3和HLA-G）相关的免疫逃逸机制进行综述。     

衣原体抗宿主细胞凋亡调控机制研究进展

衣原体为完成发育周期以及逃避宿主免疫,进化形成一整套机制以实现持续性感染并对宿主细胞进行调控,抑制宿主细胞凋亡。细胞感染衣原体后,早期可以抑制Caspase酶系,抑制相关信号转导途径,且胞内线粒体发生一系列结构和功能的变化,抑制凋亡因子释放,一系列因子协同作用,抑制宿主细胞凋亡。本文从凋亡途径、凋亡蛋白、凋亡信号通路三个主要方面作了衣原体抑制宿主细胞凋亡机制概述,对进一步了解衣原体发育及其致病机制提供了新的研究思路。     

布鲁氏菌逃逸宿主的抗感染免疫机制

布鲁氏菌病是由布鲁氏菌引发的世界范围的人兽共患传染病。布鲁氏菌为兼性胞内寄生菌,无典型的毒力因子,但却有很强的致病性,常引发人和动物的慢性感染。逃逸宿主的抗感染免疫反应是慢性感染的先决条件,这种能力对于布鲁氏菌的毒力来说似乎也越来越关键。作为成功的致病性病原菌,布鲁氏菌采用"隐秘的"策略以逃避或抑制固有免疫、调节适应性免疫,从而在宿主细胞内建立长期的持续性感染。本文将围绕布鲁氏菌逃逸宿主的抗感染免疫的分子机制进行阐述,旨为阐明布鲁氏菌毒力的新见解,这很可能为布病的预防开辟新的途径。     

中医药干预癌症免疫逃逸的研究进展

免疫逃逸是指恶性肿瘤细胞通过免疫编辑过程后具备浸润、转移等恶性生物学行为,并逃脱免疫系统的监视和清除,最终促进恶性肿瘤病情发生发展的过程。除其他因素外,免疫细胞还积极影响肿瘤发展的每一步,决定了癌细胞在受威胁的微环境中生存的机会。一旦发现第一个癌细胞,抗肿瘤免疫机制就会被激活,并在原发肿瘤形成和转移过程中发挥作用。然而,免疫功能受损时,肿瘤细胞就会通过逃避或者阻挠免疫反应的机制来促进自身的增殖,就会导致肿瘤的持续性发展。而中医药干预癌症免疫逃逸机制需以“扶正”为基本原则,补益正气以治其本,增强免疫细胞对癌细胞的杀伤力,阻止癌症免疫逃逸,从而抑制癌症的发展。根据现有文献分析可知,目前通过免疫逃逸治疗癌症多用补益类药物,这可能是因为机体免疫调节功能与中医“扶正”观点相符合。因此,研究癌症免疫逃逸机制不仅能够提高治疗癌症的效率,而且通过对中医药的开发利用,能够延缓疾病的发展进程,更好的改善患者的生存质量。     

肿瘤免疫逃逸与T淋巴细胞关系的研究进展

阐明肿瘤免疫逃逸是防止肿瘤发生、诊断肿瘤发展以及治愈肿瘤的关键。肿瘤逃避免疫监视(immunosurveillance)已知与宿主免疫低下、T细胞无能,和肿瘤抗原缺失和调变、肿瘤漏逸、缺乏共刺激通路信号等相关,总结了近期研究进展,围绕肿瘤和T淋巴细胞相互关系,从T细胞对肿瘤识别和耐受、肿瘤下调识别分子导致活化T细胞丧失识别能力、肿瘤抵抗凋亡助其逃逸免疫、肿瘤通过抑制性受体和分子诱导T细胞无能耐受和凋亡、肿瘤细胞攻击T细胞逃避免疫、和肿瘤依赖Treg和MDSC抑制免疫等方面总结了理解思路,对肿瘤免疫消除(elimination)、免疫相持(equilibrium)和免疫逃逸(escape)三个阶段对抗T细胞免疫监视的机理提供参考,对肿瘤治疗具有重要意义。     

乳腺肿瘤细胞免疫逃逸机制的研究进展

乳腺癌是目前危害女性身体健康的主要恶性肿瘤之一,其发病机制十分复杂。尽管近年来对乳腺癌的治疗有了长足的发展,但仍有部分病人因未能早期发现及术后通过淋巴道与血道转移而导致死亡。乳腺癌早期诊断、治疗困难的原因主要是其肿瘤细胞具有某些逃避机体免疫监视和防御的特点,继而引起转移,造成恶化。因此,探讨乳腺癌细胞生长、转移与免疫逃避的相互关系,对更好的诊治乳腺癌具有重要的意义。本文对乳腺癌细胞逃避免疫系统的监视和杀伤机制的研究进展进行综述。     

幽门螺杆菌逃逸宿主免疫应答机制

幽门螺杆菌(Helicobacter pylori,H.pylori)感染引起机体强的胃粘膜免疫应答,机体却无法对其进行完全根除,表明幽门螺杆菌具有逃避或破坏宿主免疫应答的特性。影响H.pylori逃避或破坏宿主免疫应答的因素或途径有很多,如肽聚糖的结构性修饰、H.pylori形态的改变、脂多糖抗原表位变化、IV型分泌系统、VacA和Treg细胞的免疫抑制作用、通过抑制吞噬细胞的吞噬作用和引起吞噬细胞的凋亡等等,本文就此作一综述,为以后对H.pylori的防御和治疗提供新的线索。     

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

Tumor immune escape variants can be identified in human and experimental tumors. A variety of different strategies are used by tumor cells to avoid recognition by different immune effector mechanisms. Among these escape routes, alteration of MHC class I cell surface expression is one of the mechanisms most widely used by tumor cells. In this review we focus our attention on the T-cell immune selection of MHC class I–deficient tumor variants. Different altered MHC class I phenotypes that originate from multiple molecular mechanisms can be identified in human tumors. MHC-deficient tumor clones can escape T-cell immune responses, but are in theory more susceptible to NK-cell–mediated lysis. In this context, we also review the controversial issue of the aberrant expression of nonclassical HLA class I molecules, particularly HLA-G, in tumors. This expression may be relevant in tumor cells that have lost the capacity to interact with NK inhibitory receptors—namely, those tumor cells with no HLA-B or HLA-C expression. Most published studies have not analyzed these possibilities and do not provide information about the complete HLA-A, HLA-B, or HLA-C molecule profiles of the tumors studied. In contrast, HLA-E has been reported to be expressed in some tumor cell lines with very low HLA-A, HLA-B, and HLA-C expression, suggesting that HLA-E may indeed, in some cases, play a role by inhibiting NK lysis of cells that otherwise would be destroyed by NK cells. Finally, we provide evidence that the status of the immune system in the tumor-bearing animal is capable of defining the MHC profile of the tumor cells. In other words, MHC class I–negative metastatic colonies are produced in immunocompetent animals, and MHC class I–positive colonies in T-cell immunodeficient individuals.This article forms part of the Symposium in Writing Tumor escape from the immune response, published in Vol. 53.     

How tumors escape immune destruction and what we can do about it

There is strong circumstantial evidence that tumor progression in cancer patients is controlled by the immune system. As will be detailed below, this conclusion is based on observations that tumor progression is often associated with secretion of immune suppressive factors and/or downregulation of MHC class I antigen presentation functions. The inference is that tumors must have elaborated strategies to circumvent an apparently effective immune response. Importantly, a tumor-specific immune response cannot be detected in most individuals. While this failure is in part technical, it also suggests that the magnitude of the immune responses to which tumors have to respond is low. This raises the concern, which is the underlying theme of this commentary, that a more robust immune response elicited by deliberate vaccination will exacerbate the rate of immune escape and nullify the potential benefits of immune-based therapies. Received: 20 March 1999 / Accepted: 3 May 1999     

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy

The cytotoxic activity of T cells selects the outgrowth of tumor cells that escape from immune surveillance by different strategies. The different mechanisms that interfere with immune recognition and limit vaccination efficiency are still poorly understood. We analysed six cell lines established from different metastases of melanoma patient UKRV-Mel-20 for specific characteristics known to have an impact on the tumor-T cell interaction: (1) alterations in the HLA class I phenotype, (2) expression of Fas/CD95, and (3) expression of specific cytokines and chemokines. One of the cell lines, UKRV-Mel-20f, exhibited an HLA class I haplotype loss and just this cell line was also characterised by the expression of Fas/CD95 and of relatively high levels of proinflammatory chemokines suggesting that the cytotoxic activity of tumor-infiltrating T cells might have selected the outgrowth of this tumor cell variant. All other cell lines analysed showed no alterations in HLA class I expression, but, in contrast to UKRV-Mel-20f, expressed much lower levels of Fas/CD95 and of proinflammatory chemokines and some of them produced high levels of immunosuppressive TGF-beta1. These results suggest that in patient UKRV-Mel-20, tumor cells interfere with T cell recognition by different strategies which might partially explain why this patient did not have a clinical response to an autologous tumor cell vaccine.     

Tumor immune escape mechanisms: impact of the neuroendocrine system

Tumor cells act upon, and react to both their proximate and more distant environment, the mechanisms by which this is achieved being both autocrine and paracrine in nature. This interaction, however, takes place not only between adjacent malignant cells, but also non-malignant cells such as those of the immune system, the latter also partaking in the modeling of the tumor environment. Although tumor cells descend from normal tissue cells and thus bear in classical immunological terms ‘self signals’, it is evident that the immune system is able to recognize tumor cells as a harassment for the body and in consequence tries to eliminate these cells. On the counterpart, tumor cells acquire various characteristics which allow them to evade this immunological surveillance, and have been collectively coined with the term “tumor escape mechanisms”. This review will describe and summarize current understanding of tumor escape strategies, and also more closely elaborate on the modulatory role of the neuroendocrine system in the immune system–tumor cell interaction.     

Epigenetic regulation of immune escape genes in cancer

According to the concept of immune surveillance, the appearance of a tumor indicates that it has earlier evaded host defenses and subsequently must have escaped immunity to evolve into a full-blown cancer. Tumor escape mechanisms have focused mainly on mutations of immune and apoptotic pathway genes. However, data obtained over the past few years suggest that epigenetic silencing in cancer may be as frequent a cause of gene inactivation as are mutations. Here, we discuss the evidence that tumor immune evasion is mediated by non-mutational epigenetic events involving chromatin and that epigenetics collaborates with mutations in determining tumor progression. Since epigenetic changes are potentially reversible, the relative contribution of mutations and epigenetics, to the gene defects in any given tumor, may be a factor in determining the efficacy of treatments. We review new developments in basic chromatin mechanisms and in this context describe the rationale for the current use of epigenetic agents in cancer therapy and for a novel epigenetically generated tumor vaccine model. We emphasize that epigenetic cancer treatments are currently a ‘blunt-sword’ and suggest future directions for designing chromatin-based programs of potential value in the diagnosis and treatment of cancer.     

鹦鹉热衣原体重组主要外膜蛋白诱导小鼠免疫应答的观察

用鹦鹉热衣原体 (Chlamydiapsittaci,Cps)重组主要外膜蛋白 (RecombinantMajorOuter Membraneprotein ,r MOMP)免疫小鼠 ,观察小鼠免疫后对r MOMP和Cps菌体蛋白的免疫应答。r MOMP皮下注射免疫BALB/c小鼠 ,对照组仅注射佐剂。免疫前和第 3次免疫后 10d收集血清 ,以常规ELISA法检测抗体效价 ;MTT方法检测脾淋巴细胞对r MOMP和Cps菌体蛋白的特异性增殖反应。免疫组小鼠在免疫 38d后免疫血清中抗r MOMP的抗体效价可达 1∶2× 10 4,抗Cps菌体蛋白的抗体效价为 1∶4× 10 3 ;脾淋巴细胞对r MOMP和Cps菌体蛋白的增殖指数明显高于佐剂对照组 (p <0 .0 1,具有显著性意义。r MOMP在小鼠体内可诱导Cps特异性的体液免疫和细胞免疫应答 ,说明具有较好的免疫原性     

昆虫免疫识别与病原物免疫逃避机理研究进展

昆虫在长期进化过程中形成复杂的天然免疫系统,病原识别是启动下游免疫反应的第一步,这一过程主要是由不同的模式识别蛋白来完成的。目前发现并鉴定的昆虫模式识别蛋白主要包括肽聚糖识别蛋白、类免疫球蛋白、β-1,3-葡聚糖结合蛋白、C型凝集素及具多功能的载脂蛋白等,不同的蛋白种类具有不同的结构、功能及识别对象。与昆虫免疫识别相对应的是,不同昆虫病原物在进化过程中发展出不同策略的免疫逃避能力,以战胜宿主免疫而致病或最终杀死昆虫。本文就昆虫免疫过程中不同模式识别蛋白的结合对象、结构与功能,以及逐渐兴起的病原物通过分子伪装等进行免疫逃避的研究进展进行了综述。并在此基础上,作者就昆虫免疫与昆虫病理研究的发展方向进行了展望,认为只有当两方面研究相结合时,才能更好地揭示昆虫宿主与病原物之间免疫与抗免疫的动态相互作用过程。     

Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape

Tumor escape from the host immune response remains the major problem holding the development of immunotherapies for cancer. In this review, congenic mouse lines are discussed that differ dramatically in their ability to respond to tumors tested and, thereby, to survive or to succumb to the tumor and/or its metastases. This ability is under the control of either MHC class I or nontrivial MHC class II β genes expressed in a small subpopulation of antigen-presenting cells. Two hypotheses can explain the results obtained so far: (1) emergence of tumor cell variants that escape the host immune response in morbid mice but are eliminated in survivors, and (2) tumor-induced immunosuppression, which is either efficient or not, depending on the congenic line used. It is argued that further experimentation on these congenics will allow to choose the correct hypothesis, and to characterize the mechanism(s) of elimination of minimal residual disease and prevention of tumor escape by the immune system of survivors as well as the reason(s) for its failure in morbid mice. It is also argued that the use of these models will substantially increase the chance to resolve the controversy of poor correlation of immunotherapy testing in mice with clinical results.     

Primary and secondary immune responses of mucosal and peripheral lymphocytes during Chlamydia trachomatis infection

Chlamydia trachomatis infection is followed by the development of antigen-specific cell-mediated immunity, which is detectable as a positive lymphocyte proliferation response to the chlamydial major outer membrane protein (MOMP) antigen. To date, however, there have been no studies on the mucosal immune responses to chlamydial antigens. This study aimed to study the primary and secondary immune responses of cervical lymphocytes in response to the chlamydial antigen. Median proliferative responses were found to be significantly (P<0.05) higher in patients with chlamydial infections than in controls. The chlamydial MOMP induced significantly higher IL-6 and IL-10 and lower interferon-gamma (IFN-gamma) secretion in cervical lymphocytes of Chlamydia-positive women, resulting in a T helper 2 response. On stimulation of peripheral blood mononuclear cells (PBMC) obtained from Chlamydia-positive women with the chlamydial antigen, the median levels of IL-10, IL-12 and IFN-gamma were higher than in controls, but the differences were not significant. Our study suggests that the mucosal immune responses towards Chlamydia trachomatis are different from those of PBMCs and are more helpful in understanding the cytokine responses in the female genital tract during chlamydial infection.